Document:

SHARE PURCHASE AGREEMENT

 

This Share Purchase
Agreement (this “Agreement”) is dated as of November 22, 2013 (the “Effective Date”), between
SurePure, Inc., a Nevada corporation (the “Company”), and Regency Capital Corporation, a corporation formed
under the laws of the Turks and Caicos Islands (the “Purchaser”).

 

WHEREAS, subject to
the terms and conditions set forth in this Agreement and pursuant to Section 4(2) of the Securities Act of 1933, as amended
(the “Securities Act”), Rule 506 promulgated thereunder and Regulation S promulgated thereunder, the Company
desires to issue and sell to the Purchaser, and the Purchaser desires to purchase from the Company, securities of the Company as
more fully described in this Agreement and further to grant the Purchaser the right to acquire certain additional securities of
the Company; and

 

NOW, THEREFORE, IN
CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and
adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows:

 

ARTICLE I.

DEFINITIONS

 

1.1             
Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings
set forth in this Section 1.1:

 

“Action”
shall have the meaning given to such term in Section 3.1(j).

 

“Additional
Share Closing” means each closing of a purchase and sale of any Additional Shares.

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Board of
Directors” means the board of directors of the Company.

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.

 

“Closing”
means the Initial Closing and each Additional Share Closing.

 

“Closing Date”
means the date of the Initial Closing or a date of any Additional Share Closing, as the case shall be.

 

“Commission”
means the United States Securities and Exchange Commission.

 

    	 

    	 

    

  

“Committed
Shares” means 170,000 Shares.

 

“Commitment
Amount” shall have the meaning given to such term in Section 2.1.

 

“Common Stock”
means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities
may hereafter be reclassified or changed.

 

“Common Stock
Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time Common
Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time
convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“GAAP”
shall have the meaning given to such term in Section 3.1(h).

 

“Initial Closing”
shall have the meaning given to such term in Section 2.1(a).

 

“Lien”
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

 

“Material
Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b).

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Preferred
Stock” means shares of the Company’s Nonvoting Convertible Preferred Stock, par value $0.01 per share.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.

 

“Prospectus”
shall mean the Company’s Supplemental Prospectus as filed with the Commission on May 17, 2013.

 

“Purchase
Price” shall have the meaning given it in Section 2.3.

 

“Registration
Rights Schedule” means the Registration Rights Schedule, attached hereto as Schedule A.

 

“Regulation
S” means Regulation S promulgated by the Commission pursuant to the Securities Act, as such regulation may be amended
or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the
same purpose and effect as such regulation.

 

    	2

    	 

    

  

“Rule 144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such rule may be amended or interpreted from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such rule.

 

“SEC Reports”
shall have the meaning given to such term in Section 3.1(h).

 

“Shares”
means shares of the Company’s Common Stock.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Short Sales”
means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to
include the location and/or reservation of borrowable shares of Common Stock).

 

“Subsidiary”
means any subsidiary of the Company as set forth in the Prospectus.

 

“Trading Day”
means any day on which the Trading Market is open for business.

 

“Trading Market”
means the OTC Bulletin Board.

 

“Transaction
Documents” means this Agreement and all exhibits and schedules hereto and any other documents or agreements executed
in connection with the transactions contemplated hereunder.

 

“Transfer
Agent” means Vstock Transfer, LLC, the current transfer agent of the Company, with a mailing address of 77 Spruce Street,
Suite 201, Cedarhurst, New York 11516, and any successor transfer agent of the Company.

 

“VWAP”
means the volume weighted average price for the Shares in the Trading Market for the designated period of time, as determined by
the Company in good faith from information provided by Bloomberg LP.

 

ARTICLE II.

PURCHASE AND SALE

 

2.1           Closings.
Upon the terms and subject to the conditions set forth herein, the Company will sell to the Purchaser, and the Purchaser will purchase
from the Company, the Committed Shares for the aggregate Purchase Price of $170,000 (the “Commitment Amount”).
The Committed Shares will be purchased and sold not later than November 30, 2013 (the closing of the purchase and sale of the Committed
Shares is referred to as the “Initial Closing”). . Upon satisfaction of the conditions set forth in Section
2.4, the Initial Closing shall occur that date at the Company’s office at 405 Lexington Avenue, 25th Floor, New
York, NY 10104 or such other location as the parties shall mutually agree. At the Initial Closing, (a) the Purchaser shall deliver
the Commitment Amount to the Company in United States dollars and in immediately available funds wired in accordance with wire
transfer instructions that the Company shall provide to the Purchaser upon the execution of this Agreement, and (b) within ten
(10) Business Days following receipt of the Commitment Amount, the Company shall send the Committed Shares to the Purchaser at
its address set forth on the execution page to this Agreement

 

    	3

    	 

    

  

2.2          Option to Purchase
Additional Shares. At the option of the Purchaser to be exercised not later than January 31, 2014, the Company will sell to
the Purchaser, and the Purchaser will purchase from the Company, up to 430,000 Shares (the “Additional Shares”)
in addition to the Committed Shares on not less than five (5) Business Days’ notice to the Company. Within two (2) Business
Days after its receipt of a notice from the Purchaser stating that it will exercise its right to purchase Additional Shares under
this Section, the Company will notify the Purchaser of the applicable Purchase Price for the Additional Shares being purchased,
which Purchase Price shall, in the absence of manifest error, be binding on the Purchaser. Upon satisfaction of the covenants and
conditions set forth in Section 2.4, each Additional Share Closing shall occur at the Company’s office at 405 Lexington Avenue,
25th Floor, New York, NY 10104 or such other location as the parties shall mutually agree. At each Additional Share
Closing, (a) the Purchaser shall deliver to the Company the applicable Purchase Price times the number of Additional Shares being
purchased in United States dollars and in immediately available funds wired in accordance with wire transfer instructions that
the Company shall have most recently provided to the Purchaser, and (b) within ten (10) Business Days following receipt of the
Purchase Price therefor, the Company shall send the Shares purchased on the date of the Additional Share Closing to the Purchaser
at its address set forth on the execution page to this Agreement.

 

2.3 Purchase Price.
The purchase price (the “Purchase Price”) for the Shares shall be as follows:

 

(a) for
the Committed Shares, $1.00 per share; and

 

(b) for
the Additional Shares, the greater of (i) $1.00 per share and (ii) 92% of VWAP for the twenty (20) Trading Days ending on the third
(3rd) Trading Day prior to the date of the Additional Share Closing.

 

2.4 Closing Conditions.

 

(a) The
obligations of the Company under this Agreement in connection with each Closing are subject to the following conditions being met:

 

(i) the
accuracy in all material respects on the Closing Date of the representations and warranties of the Purchaser contained herein (unless
as of a specific date referred to therein, in which case they shall be accurate as of such date); and

 

(ii) all
obligations, covenants and agreements of the Purchaser required to be performed at or prior to the Closing Date shall have been
performed.

 

(b) The
obligations of the Purchaser under this Agreement in connection with each Closing are subject to the following conditions being
met:

 

    	4

    	 

    

  

(i) the
accuracy in all material respects when made and on the Closing Date of the representations and warranties of the Company contained
herein (unless as of a specific date referred to therein, in which case they shall be accurate as of such date); and

 

(ii) all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed.

 

2.5 Registration
Rights. The Shares purchased by the Purchaser shall have the benefit of the registration rights provided in the Registration
Rights Schedule.

 

ARTICLE III.

REPRESENTATIONS AND
WARRANTIES

 

3.1 Representations
and Warranties of the Company. The Company hereby makes the following representations and warranties to the Purchaser as of
the Effective Date and as of each Closing Date (unless as of a specific date referred to herein):

 

(a) Subsidiaries.
All of the direct and indirect Subsidiaries of the Company are set forth in the Prospectus. The Company owns, directly or indirectly,
all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding
shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar
rights to subscribe for or purchase securities.

 

(b) Organization
and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company
nor any Subsidiary is in violation or default of any of the provisions of its respective certificate or articles of incorporation,
bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business
and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity
or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business,
prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material
adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction
Document (any of (i), (ii) or (iii), a “Material Adverse Effect”), and no Proceeding has been instituted
in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

 

(c) Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by
it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company
and no further action is required by the Company, the Board of Directors or the Company’s stockholders in connection herewith
or therewith. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been)
duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and
binding obligation of the Company enforceable against the Company in accordance with its terms, except: (i) as limited by
general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions
may be limited by applicable law.

 

    	5

    	 

    

  

(d) No Conflicts.
The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party,
the issuance and sale of the Shares and the consummation by it of the transactions contemplated hereby and thereby do not and will
not: (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate or articles of
incorporation, bylaws or other organizational or charter documents, (ii) result in the creation of any Lien upon any of the
properties or assets of the Company or any Subsidiary, conflict with, or constitute a default (or an event that with notice or
lapse of time or both would become a default) under, , or give to others any rights of termination, amendment, acceleration or
cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing
a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which
any property or asset of the Company or any Subsidiary is bound or affected or (iii) conflict with or result in a violation
of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to
which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property
or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as
could not have or reasonably be expected to result in a Material Adverse Effect.

 

(e) Filings, Consents
and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or
make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person
in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than the filings
required pursuant to the Registration Rights Schedule.

 

(f) Issuance of
the Shares. The Shares are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents,
will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions
on transfer provided for in the Transaction Documents.

 

(g) Capitalization.
The capitalization of the Company is as set forth in the Prospectus. As of September 30, 2013, there were issued and outstanding
20,210,631 shares of Preferred Stock and 38,346,301 shares of Common Stock. No Person has any right of first refusal, preemptive
right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents.
There are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating
to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to
subscribe for or acquire any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company
or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance and
sale of the Shares will not obligate the Company to issue shares of Common Stock or other securities to any Person and will not
result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of
such securities. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid
and nonassessable, have been issued in compliance with all applicable federal and state securities laws, and none of such outstanding
shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval
or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Shares under
this Agreement. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s
capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s
stockholders.

 

    	6

    	 

    

  

(h) SEC Reports;
Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required to be filed
by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
two years preceding the Effective Date (or such shorter period as the Company was required by law or regulation to file such material)
(the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred
to herein as the “SEC Reports”) on a timely basis or has received a valid extension of such time of filing and
has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied
in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports
that were filed on or after December 12, 2012, when filed, contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material
respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect
at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting
principles applied on a consistent basis during the periods involved (“GAAP”), except as may be otherwise specified
in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes
required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries
as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of
unaudited statements, to normal, immaterial, year-end audit adjustments.

 

(i) Material Changes;
Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included within
the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof: (i) there has
been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect,
(ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued
expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be
reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the
Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of
cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its
capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant
to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Shares contemplated by this Agreement, no event, liability, fact, circumstance,
occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its
Subsidiaries or their respective businesses, properties, operations, assets or financial condition, that would be required to be
disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been
publicly disclosed.

 

    	7

    	 

    

  

(j) Litigation.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company,
threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator,
governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”)
which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or
the Shares or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse
Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving
a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not
been, and to the knowledge of the Company, there is no investigation by the Commission, whether pending or contemplated, involving
the Company or any current director or officer of the Company. The Commission has not issued any stop order or other order suspending
the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities
Act.

 

(k) Certain Fees.
No brokerage or finder’s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial
advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated
by the Transaction Documents. The Purchaser shall have no obligation with respect to any fees or with respect to any claims made
by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions
contemplated by the Transaction Documents.

 

(l) Private Placement.
Assuming the accuracy of the Purchaser’s representations and warranties set forth in Section 3.2, no registration under
the Securities Act is required for the offer and sale of the Shares by the Company to the Purchaser as contemplated hereby.

 

(m) Listing and
Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the
Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. The Company has not, in the 12 months preceding the Effective Date, received notice from any trading market
to the effect that the Company is not in compliance with the listing or maintenance requirements of such trading market. The Company
is in compliance with all such listing and maintenance requirements.

 

    	8

    	 

    

  

(n) Disclosure.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor any other Person acting on its behalf has provided the Purchaser or its agents or counsel with any
information that it believes constitutes or might constitute material, non-public information. The Company understands and confirms
that the Purchaser will rely on the foregoing representation in effecting transactions in securities of the Company. All of the
disclosures furnished by or on behalf of the Company to the Purchaser regarding the Company and its Subsidiaries, their respective
businesses and the transactions contemplated hereby are true and correct and do not contain any untrue statements of a material
fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under
which they were made, not misleading. The Company acknowledges and agrees that the Purchaser is not making or has not made any
representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2.

 

3.2 Representations
and Warranties of the Purchaser. The Purchaser hereby represents and warrants as of the Effective Date and as of each Closing
Date to the Company as follows (unless as of a specific date therein):

 

(a) Organization;
Authority. The Purchaser is an entity duly incorporated or formed, validly existing and in good standing under the laws of
the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar
power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to
carry out its obligations thereunder. The execution and delivery of the Transaction Documents and performance by the Purchaser
of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of the Purchaser. Each Transaction Document to which it
is a party has been duly executed by the Purchaser, and when delivered by the Purchaser in accordance with the terms thereof, will
constitute the valid and legally binding obligation of the Purchaser, enforceable against it in accordance with its terms, except:
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other
laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to
the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.

 

(b) Own Account.
The Purchaser understands that the Shares are “restricted securities” and have not been registered under the Securities
Act or any applicable state securities law and is acquiring the Shares as principal for its own account and not with a view to
or for distributing or reselling such Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, has no present intention of distributing any of such Shares in violation of the Securities Act or any applicable state securities
law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution
of such Shares in violation of the Securities Act or any applicable state securities law. The Purchaser is acquiring the Shares
hereunder in the ordinary course of its business.

 

    	9

    	 

    

  

(c) Purchaser Status.
At the time the Purchaser was offered the Shares, it was, and as of the date hereof it is, it was an “accredited investor”
as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act and a person other than a “U.S. Person”
as defined in Rule 902 under the Securities Act. The Purchaser is not acquiring the Shares for the benefit of any U.S. Person.
The Purchaser will be the sole beneficial owner of the Shares, and the Purchaser has not pre-arranged any sale with respect to
any of the foregoing to any persons in the United States. For purposes of this representation, the “United States”
means the United States of America, its territories and possessions, any state of the United States and the District of Columbia.
The Purchaser is outside the United States as of the date of the execution and delivery of this Agreement and will be outside the
United States at the time of each Closing; provided, that delivery of the Shares may be effected within the United States
through the Purchaser’s agent as long as the Purchaser is outside the United States at the time of any such delivery. The
purchase of the Shares under this Agreement is not part of a plan or scheme to evade the registration provisions of the Securities
Act.

 

(d) Experience of
the Purchaser. The Purchaser has such knowledge, sophistication and experience in business and financial matters so as to be
capable of evaluating the merits and risks of the prospective investment in the Shares, and has so evaluated the merits and risks
of such investment. The Purchaser is able to bear the economic risk of an investment in the Shares and is able to afford a complete
loss of such investment. The Purchaser and its advisors, if any, have been furnished with all materials relating to the business,
financial condition and results of operations of the Company, and materials relating to the offer and sale of the Shares, that
have been requested by the Purchaser or its advisors, if any. The Purchaser acknowledges and understands that its investment in
the Shares involves a significant degree of risk.

 

(e) Certain Transactions
and Confidentiality. Other than consummating the transactions contemplated under the Transactional Documents, the Purchaser
has not directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding with the Purchaser, executed
any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time
that the Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company
setting forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof.
Other than to other Persons party to this Agreement, the Purchaser has maintained the confidentiality of all disclosures made to
it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing,
for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect
to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar
transactions in the future.

 

    	10

    	 

    

  

ARTICLE IV.

OTHER AGREEMENTS
OF THE PARTIES

 

4.1 Transfer Restrictions.

 

(a) The Shares may
only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Shares other than
pursuant to an effective registration statement, under Rule 144 or Regulation S, to the Company or to an Affiliate of the Purchaser,
the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably
acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect
that such transfer does not require registration of such transferred Shares under the Securities Act. As a condition of transfer,
any such transferee shall agree in writing to be bound by the terms of this Agreement and shall have the rights and obligations
of the Purchaser under this Agreement.

 

(b) As long as is required
by the Securities Act, certificates representing the Shares shall bear a legend in the following form:

 

THIS SECURITY HAS NOT
BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE
OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL
BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

4.2 Furnishing of
Information; Public Information. Until the Purchaser owns no Shares, the Company covenants to maintain the registration of
the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in respect thereof
and file within the applicable grace period) all reports required to be filed by the Company after the Effective Date pursuant
to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.

 

4.3 Securities Laws
Disclosure; Publicity. The Company shall, by 9:00 a.m. (New York City time) on or prior to the fourth Business Day immediately
following the date to which this Agreement has been executed by the Company and the Purchaser, file with the Commission a Current
Report on Form 8-K disclosing the material terms of the transactions contemplated hereby and attaching this Agreement as an exhibit
with the Commission. From and after the filing of such Current Report on Form 8-K, the Company represents to the Purchaser that
the Company shall have publicly disclosed all material, non-public information delivered to the Purchaser by the Company or any
of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection with the transactions contemplated
by the Transaction Documents. The Company and the Purchaser shall consult with each other in issuing any other press releases with
respect to the transactions contemplated hereby, and neither the Company nor the Purchaser shall issue any such press release nor
otherwise make any such public statement without the prior consent of the Company, with respect to any press release of the Purchaser,
or without the prior consent of the Purchaser, with respect to any press release of the Company, which consent shall not unreasonably
be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide
the other party with prior notice of such public statement or communication.

 

    	11

    	 

    

  

4.4 Non-Public Information.
Neither the Company, nor any other Person acting on its behalf, will provide the Purchaser or its agents or counsel with any information
that the Company believes constitutes material non-public information, unless prior thereto the Purchaser shall have entered into
a written agreement with the Company regarding the confidentiality and use of such information. The Company understands and confirms
that the Purchaser is relying on the foregoing covenant in effecting transactions in securities of the Company.

 

4.5 Use of Proceeds.
The Company shall use the net proceeds from the sale of the Shares hereunder for working capital purposes in compliance with applicable
law.

 

ARTICLE V.

MISCELLANEOUS

 

5.1 Fees and Expenses.
Each party shall pay the fees and expenses of its advisors, counsel, accountants and other experts, if any, and all other expenses
incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company
shall pay all Transfer Agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of any Shares
to the Purchaser.

 

5.2 Entire Agreement.
The Transaction Documents, together with the exhibits and schedules hereof and thereto, contain the entire understanding of the
parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written,
with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

5.3 Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City
time) on a Business Day, (b) the Business Day after the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number set forth on the signature pages attached hereto on a day that is not a Business Day or later
than 5:30 p.m. (New York City time) on any Business Day, (c) the second (2nd) Business Day following the date of
mailing, if sent by U.S. nationally recognized overnight courier service with confirmed instructions for next-day delivery or (d) upon
actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall
be as follows:

 

    	12

    	 

    

 

 

	
        For the Company:

         

         

         

        405 Lexington Avenue, 25th Floor

         

        New York, NY 10174

         

        Attention: Stephen M. Robinson

         

        Chief Financial Officer

         

         

         

        With a copy to (which shall not constitute
        notice):

         

         

         

        William A. Newman, Esq.

         

        Barton LLP

         

        420 Lexington Ave., 18th Floor

         

        New York, NY 10170

         

         

         
	
        For the Purchaser:

         

         

         

        c/o 8 Eu Tong Sen Street

         

        # 12-82 The Central

         

        Clarke Quay

         

        Singapore 059818

         

        Attention: Mr.
        Richard Wilson

         

 

 

5.4 Amendments;
Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed,
in the case of an amendment, by the Company and the Purchaser or, in the case of a waiver, by the party against whom enforcement
of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of this
Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any
manner impair the exercise of any such right.

 

5.5 Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.

 

5.6 Successors and
Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.
The Purchaser may assign any or all of its rights under this Agreement to any Person to whom the Purchaser assigns or transfers
any Shares; provided, that such transferee agrees in writing to be bound, with respect to the transferred Shares, by the
provisions of the Transaction Documents that apply to the Purchaser.

 

5.7 No Third-Party
Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

    	13

    	 

    

  

5.8 Governing Law.
All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of
conflicts of law thereof. All Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated
by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors,
officers, stockholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York, Borough of Manhattan. Each party hereby irrevocably submits to the exclusive jurisdiction of the
state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement
of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper
or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents
to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action,
suit or proceeding to enforce any provisions of the Transaction Documents, then the prevailing party in such action, suit or proceeding
shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such action or proceeding.

 

5.9 Survival.
The representations and warranties contained herein shall survive each of the Closings and the deliveries of the Shares for a period
of six (6) months.

 

5.10 Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. If any signature is delivered by facsimile transmission or by e-mail
delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing
(or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature
page were an original thereof.

 

5.11 Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.

 

    	14

    	 

    

  

5.12 Replacement
of Shares. If any certificate or instrument evidencing any Shares is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu
of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the
Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Shares.

 

5.13 Construction.
Each of the parties and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and,
therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference
to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock
splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the Effective Date.

 

5.14 WAIVER OF JURY
TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH
KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

 

    	15

    	 

    

  

IN WITNESS WHEREOF,
the parties hereto have caused this Share Purchase Agreement to be duly executed by their respective authorized signatories as
of the date first indicated above.

 

	 	
        SUREPURE, INC.

         

        By:  /s/ Stephen M. Robinson

         

        Name: Stephen M. Robinson

         

        Title: Chief Financial Officer

         

        Fax:

         

	 	 
	 	
        REGENCY CAPITAL CORPORATION

         

        By  /s/Richard Wilson

         

        Name: Richard Wilson

         

        Title: Director

         

        Fax:

         

	 	 

 

    	16

    	 

    

  

Schedule
A 

 

REGISTRATION
RIGHTS SCHEDULE 

 

This Registration
Rights Schedule (this “Schedule”) is attached to and is incorporated by reference into the Share Purchase Agreement
(the “Share Purchase Agreement”), dated as of November 22, 2013, between SurePure, Inc., a Nevada corporation,
and Regency Capital Corporation, a corporation formed under the laws of the Turks and Caicos Islands.

   

		1.	Definitions.

 

Capitalized
terms used and not otherwise defined herein that are defined in the Share Purchase Agreement shall have the meanings given such
terms in the Share Purchase Agreement. As used in this Schedule, the following terms shall have the following meanings:

 

“Advice”
shall have the meaning set forth in Section 6(c).

 

“Effectiveness
Period” shall have the meaning set forth in Section 2(a).

 

“Holder”
or “Holders” means the holder or holders, as the case may be, from time to time of Registrable Securities.

 

“Indemnified
Party” shall have the meaning set forth in Section 5(c).

 

“Indemnifying
Party” shall have the meaning set forth in Section 5(c).

 

“Losses”
shall have the meaning set forth in Section 5(a).

 

“Plan
of Distribution” means the Plan of Distribution attached hereto as Annex 1.

 

“Prospectus”
means the prospectus included in the Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated
by the Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the
terms of the offering of any portion of the Registrable Securities covered by the Registration Statement, and all other amendments
and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to
be incorporated by reference in such Prospectus.

 

“Registrable
Securities” means, as of any date of determination, (a) all of the shares of Common Stock issued under the Share
Purchase Agreement and (b) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization
or similar event with respect to the shares of Common Stock issued under the Share Purchase Agreement; provided, that any
such Registrable Securities shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness
of any, or file another, Registration Statement hereunder with respect thereto) for so long as (a) the Registration Statement
with respect to the sale of such Registrable Securities is declared effective by the Commission under the Securities Act and such
Registrable Securities have been disposed of by the Holder in accordance with such effective Registration Statement, (b) such
Registrable Securities have been previously sold in accordance with Rule 144, or (c) such Registrable Securities become eligible
for resale without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 as set forth
in a written opinion letter to such effect, addressed, delivered and acceptable to the Company’s transfer agent and the affected
Holders (assuming that such securities and any securities issuable upon exercise, conversion or exchange of which, or as a dividend
upon which, such securities were issued or are issuable, were at no time held by any Affiliate of the Company), as reasonably determined
by the Company, upon the advice of counsel to the Company.

 

    	17

    	 

    

  

“Registration
Statement” means any registration statement required to be filed pursuant to Section 2(a) of this Schedule, including
(in each case) the Prospectus, amendments and supplements to any such registration statement or Prospectus, including pre- and
post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference
in any such registration statement.

 

“Rule
415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such rule.

 

“Rule
424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such rule.

 

“SEC
Guidance” means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements
or requests of the Commission staff and (ii) the Securities Act.

 

		2.	Piggy-Back Registration.

 

(a)   
If, at any time prior to the first anniversary of the Effective Date (as defined in the Share Purchase Agreement) the Company
shall determine to prepare and file with the Commission a registration statement relating to an offering for its own account or
a resale offering by any of its stockholders under the Securities Act of any of its equity securities, other than on Form S-4 or
Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely
in connection with any acquisition of any entity or business or equity securities issuable in connection with the Company’s
stock option or other employee benefit plans, then the Company shall deliver to each Holder a written notice of such determination
and, if within fifteen (15) days after the date of the delivery of such notice, any such Holder shall so request in writing, the
Company shall include in the Registration Statement all or any part of such Registrable Securities such Holder requests to be registered;
provided, that the Company shall not be required to register any Registrable Securities pursuant to this Section that are
(i) eligible for resale pursuant to Rule 144 (without volume restrictions or current public information requirements) promulgated
by the Commission pursuant to the Securities Act or (ii) the subject of a then effective registration statement. The Registration
Statement shall contain substantially the “Plan of Distribution” attached hereto as Annex 1 with respect to
the Registrable Shares. Subject to the terms of this Schedule, the Company shall use its reasonable best efforts to cause the Registration
Statement filed under this Section to be declared effective under the Securities Act as promptly as reasonably practical after
the filing thereof and shall use its reasonable best efforts to keep the Registration Statement continuously effective under the
Securities Act until all Registrable Securities covered by the Registration Statement (i) have been sold, thereunder or pursuant
to Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement
for the Company to be in compliance with the current public information requirement under Rule 144, as determined by the counsel
to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to the Company’s transfer agent
and the affected Holders (the “Effectiveness Period”).

 

    	18

    	 

    

 

(b)  
If the Commission informs the Company that all of the Registrable Securities cannot, as a result of the application of Rule
415, be registered for resale as a secondary offering on a single registration statement, the Company will promptly inform each
of the Holders thereof and use its commercially reasonable efforts to file amendments to the Registration Statement as required
by the Commission, covering the maximum number of Registrable Securities permitted to be registered by the Commission on another
appropriate form.

   

(c)   
Notwithstanding any other provision of this Schedule, if the Commission or any SEC Guidance sets forth a limitation on the
number of Registrable Securities permitted to be registered on a registration statement as a secondary offering (and notwithstanding
that the Company used diligent efforts to advocate with the Commission for the registration of all or a greater portion of Registrable
Securities), unless otherwise directed in writing by a Holder as to the Registrable Securities, the number of the Registrable Securities
to be registered on the Registration Statement may be reduced by the Company it its sole discretion without prior consultation
with any Holder.

  

3.             Registration Procedures. In connection with the Company’s registration obligations under this Schedule:

   

(a)   
Each Holder will furnish to the Company a completed Selling Stockholder Notice and Questionnaire in the form attached to
this Schedule as Annex 2 within four (4) Business Days following the date on which such Holder receives a request for Annex
2 from the Company.

 

    	19

    	 

    

    

(b)  
(i) The Company shall prepare and file with the Commission such amendments, including post-effective amendments, to the
Registration Statement and the Prospectus used in connection therewith as may be necessary to keep the Registration Statement continuously
effective (subject to any requirement that a post-effective amendment be declared effective by the Commission) as to the Registrable
Securities for the Effectiveness Period and prepare and file with the Commission such additional registration statements to register
for resale under the Securities Act all of the Registrable Securities subject to any SEC Guidance that sets forth a limitation
on the number of Registrable Securities permitted to be registered on a particular registration statement; (ii) cause the
related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Schedule),
and, as so supplemented or amended, to be filed pursuant to Rule 424; (iii) respond as promptly as reasonably possible to
any comments received from the Commission with respect to the Registration Statement or any amendment; and (iv) comply in
all material respects with the applicable provisions of the Securities Act and the Exchange Act with respect to the disposition
of all Registrable Securities covered by the Registration Statement during the Effectiveness Period in accordance (subject to the
terms of this Schedule) with the intended methods of disposition by the Holders thereof set forth in the Registration Statement
as so amended or in such Prospectus as so supplemented.

   

(c)   
[reserved]

   

(d)  
The Company shall notify the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through
(vi) hereof, be accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made)
as promptly as reasonably possible (i)(A) when the Prospectus or any Prospectus supplement or post-effective amendment to the Registration
Statement is proposed to be filed (but not including (i) any Exchange Act filing or (ii) any supplement or post-effective
amendment to a registration statement that is not related to such Holder’s Registrable Securities), (B) when the Commission
notifies the Company whether there will be a “review” of the Registration Statement and whenever the Commission comments
in writing on the Registration Statement, and (C) with respect to the Registration Statement or any post-effective amendment,
when the same has become effective, (ii) of any request by the Commission or any other federal or state governmental authority
for amendments or supplements to the Registration Statement or Prospectus or for additional information, (iii) of the issuance
by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of the Registration
Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose, (iv) of
the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification
of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such
purpose, (v) of the occurrence of any event or passage of time that makes the financial statements included in the Registration
Statement ineligible for inclusion therein or any statement made in the Registration Statement or Prospectus or any document incorporated
or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to the Registration
Statement, Prospectus or other documents so that, in the case of the Registration Statement or the Prospectus, as the case may
be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and (vi) of
the occurrence or existence of any pending corporate development with respect to the Company that the Company believes may be material
and that, in the determination of the Company, makes it not in the best interest of the Company to allow continued availability
of the Registration Statement or Prospectus; provided, that in no event shall any such notice contain any information which
would constitute material, non-public information regarding the Company or any of its Subsidiaries.

 

    	20

    	 

    

 

(e)   
The Company shall use its reasonable best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any
order stopping or suspending the effectiveness of the Registration Statement, or (ii) any suspension of the qualification
(or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable
moment.

   

(f)   
The Company shall furnish to each Holder, without charge, at least one conformed copy of the Registration Statement and
each amendment thereto, including financial statements and schedules, all documents incorporated or deemed to be incorporated therein
by reference to the extent requested by such Holder, and all exhibits to the extent requested by such Holder (including those previously
furnished or incorporated by reference) promptly after the filing of such documents with the Commission; provided, that
any such item which is available on the EDGAR system (or successor thereto) need not be furnished in physical form.

   

(g)  
Subject to the terms of this Schedule, the Company hereby consents to the use of such Prospectus and each amendment or supplement
thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus
and any amendment or supplement thereto, except after the giving of any notice pursuant to clauses (iii) through (vi) of Section 3(d).

 

    	21

    	 

    

  

(h)  
If requested by a Holder, the Company shall cooperate with such Holder to facilitate the timely preparation and delivery
of certificates representing Registrable Securities to be delivered to a transferee pursuant to the Registration Statement, which
certificates shall be free, to the extent permitted by this Schedule, of all restrictive legends, and to enable such Registrable
Securities to be in such denominations and registered in such names as any such Holder may request.

  

(i)    
Upon the occurrence of any event contemplated by clauses (iii) through (vi) of Section 3(d), as promptly as reasonably
possible under the circumstances taking into account the Company’s good faith assessment of any adverse consequences to the
Company and its stockholders of the premature disclosure of such event, the Company shall prepare a supplement or amendment, including
a post-effective amendment, to the Registration Statement or a supplement to the related Prospectus or any document incorporated
or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, neither
the Registration Statement nor such Prospectus will contain an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they
were made, not misleading. If the Company notifies the Holders in accordance with clauses (iii) through (vi) of Section 3(d)
above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall
suspend use of such Prospectus. The Company will use its reasonable best efforts to ensure that the use of the Prospectus may be
resumed as promptly as is practicable. The Company shall be entitled to exercise its right under this Section 3(i) to suspend
the availability of the Registration Statement and Prospectus for a period not to exceed 120 calendar days (which need not be consecutive
days) in any 12-month period.

   

(j)    
The Company shall comply with all applicable rules and regulations of the Commission in connection with obtaining and maintaining
the effectiveness of the Registration Statement required to be filed and maintained with the Commission under this Schedule.

  

(k)  
The Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of
Common Stock beneficially owned by such Holder and, if required by the Commission, the natural persons thereof that have voting
and dispositive control over such shares

 

    	22

    	 

    

   

4.              Registration Expenses. All fees and expenses incident to the performance of or compliance with, the provisions of
this Schedule by the Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to the Registration
Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration
and filing fees (including, without limitation, fees and expenses of the Company’s counsel and independent registered public
accountants) (A) with respect to filings made with the Commission, (B) with respect to filings required to be made with
any trading market on which the Common Stock is then listed for trading, (C) in compliance with applicable state securities
or Blue Sky laws reasonably agreed to by the Company in writing (including, without limitation, fees and disbursements of counsel
for the Company in connection with Blue Sky qualifications or exemptions of the Registrable Securities), (ii) printing expenses
(including, without limitation, expenses of printing certificates for Registrable Securities), (iii) messenger, telephone
and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance,
if the Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection
with the provisions of this Schedule. In addition, the Company shall be responsible for all of its internal expenses incurred in
connection with the consummation of the transactions contemplated by the provisions of this Schedule (including, without limitation,
all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit
and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required
hereunder. In no event shall the Company be responsible for any broker or similar commissions of any Holder.

   

		5.	Indemnification.

 

(a)   
Indemnification by the Company. The Company shall, notwithstanding any termination of its other obligations under
this Schedule, indemnify and hold harmless each Holder, the officers, directors, members, partners, agents, brokers (including
brokers who offer and sell Registrable Securities as principal as a result of a pledge or any failure to perform under a margin
call of Common Stock) and employees (and any other Persons with a functionally equivalent role of a Person holding such titles,
notwithstanding a lack of such title or any other title) of each of them, each Person who controls any such Holder (within the
meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, members,
stockholders, partners, agents and employees (and any other Persons with a functionally equivalent role of a Person holding such
titles, notwithstanding a lack of such title or any other title) of each such controlling Person, to the fullest extent permitted
by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable
attorneys’ fees) and expenses (collectively, “Losses”), as incurred, arising out of or relating to (1) any
untrue or alleged untrue statement of a material fact contained in the Registration Statement, any Prospectus or any form of prospectus
or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged
omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus
or supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation or alleged
violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder,
in connection with the performance of its obligations under the provisions of this Schedule, except to the extent, but only to
the extent, that (i) such untrue statements or omissions are based solely upon information regarding such Holder furnished
in writing to the Company by such Holder expressly for use therein, or to the extent that such information relates to such Holder
or such Holder’s proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing
by such Holder expressly for use in the Registration Statement, such Prospectus or in any amendment or supplement thereto (it being
understood that the Holder has approved Annex 1 hereto for this purpose) or (ii) in the case of an occurrence of an
event of the type specified in Section 3(d)(iii)-(vi), the use by such Holder of an outdated, defective or otherwise unavailable
Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated, defective or otherwise unavailable
for use by such Holder and prior to the receipt by such Holder of the Advice, but only if and to the extent that following the
receipt of the Advice the misstatement or omission giving rise to such Loss would have been corrected. The Company shall notify
the Holders promptly of the institution, threat or assertion of any Proceeding arising from or in connection with the provisions
of this Schedule of which the Company is aware. Such indemnity shall remain in full force and effect regardless of any investigation
made by or on behalf of such indemnified person and shall survive the transfer of any Registrable Securities by any of the Holders.

 

    	23

    	 

    

 

(b)  
Indemnification by Holders. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company,
its directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the
Securities Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons,
to the fullest extent permitted by applicable law, from and against all Losses, as incurred, to the extent arising out of or based
solely upon: (x) such Holder’s failure to comply with any applicable prospectus delivery requirements of the Securities
Act through no fault of the Company or (y) any untrue or alleged untrue statement of a material fact contained in the Registration
Statement, any Prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating
to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein
(in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading
(i) to the extent, but only to the extent, that such untrue statement or omission is contained in any information so furnished
in writing by such Holder to the Company expressly for inclusion in the Registration Statement or such Prospectus or (ii) to
the extent, but only to the extent, that such information relates to such Holder’s proposed method of distribution of Registrable
Securities and was reviewed and expressly approved in writing by such Holder expressly for use in the Registration Statement (it
being understood that the Holder has approved Annex 1 hereto for this purpose), such Prospectus or in any amendment or supplement
thereto or (iii) in the case of an occurrence of an event of the type specified in Section 3(d)(iii)-(vi), to the extent,
but only to the extent, related to the use by such Holder of an outdated, defective or otherwise unavailable Prospectus after the
Company has notified such Holder in writing that the Prospectus is outdated, defective or otherwise unavailable for use by such
Holder and prior to the receipt by such Holder of the Advice, but only if and to the extent that following the receipt of the Advice
the misstatement or omission giving rise to such Loss would have been corrected. In no event shall the liability of any selling
Holder under this Section 5(b) be greater in amount than the dollar amount of the net proceeds received by such Holder upon
the sale of the Registrable Securities giving rise to such indemnification obligation.

 

    	24

    	 

    

 

(c)   
Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled
to indemnity hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from
whom indemnity is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall have the right
to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment
of all fees and expenses incurred in connection with defense thereof; provided, that the failure of any Indemnified Party
to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Schedule, except
(and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject
to appeal or further review) that such failure shall have materially and adversely prejudiced the Indemnifying Party. An Indemnified
Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the
fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying
Party has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume
the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding or
(3) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the
Indemnifying Party, and counsel to the Indemnified Party shall reasonably believe that a material conflict of interest is likely
to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified
Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party,
the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of no more than
one separate counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any settlement
of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld, conditioned or delayed.
No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding
in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified
Party from all liability on claims that are the subject matter of such Proceeding.

 

    	25

    	 

    

   

Subject to
the terms of this Schedule, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to
the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this
Section) shall be paid to the Indemnified Party, as incurred, within ten (10) Business Days after written notice thereof to the
Indemnifying Party; provided, that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion
of such fees and expenses applicable to such actions for which such Indemnified Party is finally determined by a court of competent
jurisdiction (which determination is not subject to appeal or further review) not to be entitled to indemnification hereunder.

  

(d)  
Contribution. If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient
to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable
by such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified
Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable
considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among
other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or
alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party
or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent
such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include,
subject to the limitations set forth in this Schedule, any reasonable attorneys’ or other fees or expenses incurred by such
party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification
provided for in this Section was available to such party in accordance with its terms.

 

The parties
hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro
rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in
the immediately preceding paragraph. Notwithstanding the provisions of this Section 5(d), no Holder shall be required to contribute
pursuant to this Section 5(d), in the aggregate, any amount in excess of the net proceeds actually received by such Holder
from the sale of the Registrable Securities subject to the Proceeding ..

 

    	26

    	 

    

  

The indemnity
and contribution agreements contained in the provisions of this Schedule are in addition to any liability that the Indemnifying
Parties may have to the Indemnified Parties.

 

		6.	Miscellaneous.

 

(a)   
Remedies. If a breach by the Company or by a Holder of any of their respective obligations under this Schedule occurs,
each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this
Schedule, including recovery of damages, shall be entitled to specific performance of its rights under this Schedule.

   

(b)  
Compliance. Each Holder will comply with the prospectus delivery requirements of the Securities Act as applicable
to it (unless an exemption therefrom is available) in connection with sales of Registrable Securities pursuant to the Registration
Statement.

  

(c)   
Discontinued Disposition. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of
a notice from the Company of the occurrence of any event of the kind described in Section 3(d)(iii) through (vi), such Holder
will forthwith discontinue disposition of such Registrable Securities under the Registration Statement until it is advised in writing
(the “Advice”) by the Company that the use of the applicable Prospectus (as it may have been supplemented or
amended) may be resumed. The Company will use its reasonable best efforts to ensure that the use of the Prospectus may be resumed
as promptly as is practicable.

  

(d)  
Amendments and Waivers. The provisions of this Schedule, including the provisions of this sentence, may not be amended,
modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall
be in writing and signed by the Company and the Holders of a majority or more of the then outstanding Registrable Securities.

   

(e)   
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder
shall be delivered as set forth in the Share Purchase Agreement.

 

    	27

    	 

    

 

(f)   
No Inconsistent Agreements. If there is any inconsistency between the provisions of this Schedule and the Share Purchase
Agreement, the provisions of the Share Purchase Agreement shall prevail.

  

(g)  
Severability. If any term, provision, covenant or restriction of this Schedule is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result
as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention
of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any
of such that may be hereafter declared invalid, illegal, void or unenforceable.

  

(h)  
Headings. The headings in this Schedule are for convenience only, do not constitute a part of this Schedule and shall
not be deemed to limit or affect any of the provisions hereof.

 

    	28

    	 

    

 

Annex 1

 

Plan of
Distribution

 

Each Selling
Stockholder (the “Selling Stockholders”) of the securities and any of their pledgees, assignees and successors-in-interest
may, from time to time, sell any or all of their securities covered hereby on the OTC Bulletin Board or any stock exchange, market
or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices.
A Selling Stockholder may use any one or more of the following methods when selling securities:

 

		·	ordinary brokerage transactions and transactions in which the broker-dealer
solicits purchasers;

   

		·	block trades in which the broker-dealer will attempt to sell the securities
as agent but may position and resell a portion of the block as principal to facilitate the transaction;

  

		·	purchases by a broker-dealer as principal and resale by the broker-dealer
for its account;

  

		·	an exchange distribution in accordance with the rules of the applicable exchange;

  

		·	privately negotiated transactions;

  

		·	settlement of short sales;

  

		·	in transactions through broker-dealers that agree with the Selling Stockholders
to sell a specified number of such securities at a stipulated price per security;

  

		·	through the writing or settlement of options or other hedging transactions,
whether through an options exchange or otherwise;

  

		·	a combination of any such methods of sale; or

  

		·	any other method permitted pursuant to applicable law.

 

The Selling
Stockholders may also sell securities under Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”),
if available, rather than under this Prospectus.

 

    	1

    	 

    

  

Broker-dealers
engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction
not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction
a markup or markdown in compliance with FINRA IM-2440.

 

In connection
with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions
they assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions,
or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter
into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities
which require the delivery to such broker-dealer or other financial institution of securities offered by this Prospectus, which
securities such broker-dealer or other financial institution may resell pursuant to this Prospectus (as supplemented or amended
to reflect such transaction).

 

The Selling
Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters”
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each Selling Stockholder has informed us that it does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the securities. In no event shall any broker-dealer receive fees, commissions
and markups which, in the aggregate, would exceed eight percent (8%).

 

The Company
is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company
has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities
under the Securities Act.

 

Because Selling
Stockholders may be deemed to be “underwriters” within the meaning of the Securities Act, they will be subject to the
prospectus delivery requirements of the Securities Act including Rule 172 thereunder. In addition, any securities covered by this
Prospectus which qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than under this
Prospectus. The Selling Stockholders have advised us that there is no underwriter or coordinating broker acting in connection with
the proposed sale of the resale securities by the Selling Stockholders.

 

We agreed
to keep this Prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders
without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144 and without the requirement
for the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule
of similar effect or (ii) all of the securities have been sold pursuant to this Prospectus or Rule 144 under the Securities
Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers
if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not
be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or
qualification requirement is available and is complied with.

  

Under applicable
rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously
engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation
M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions
of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and
sales of the common stock by the Selling Stockholders or any other person. We will make copies of this Prospectus available to
the Selling Stockholders and have informed them of the need to deliver a copy of this Prospectus to each purchaser at or prior
to the time of the sale (including by compliance with Rule 172 under the Securities Act).

 

    	2

    	 

    

 

Annex 2

 

SUREPURE,
INC.

 

Selling
Stockholder Notice and Questionnaire

 

The undersigned
beneficial owner of common stock (the “Registrable Securities”) of SurePure, Inc., a Nevada corporation (the
“Company”), understands that the Company has filed or intends to file with the Securities and Exchange Commission
(the “Commission”) the registration statement (the “Registration Statement”) for the registration
and resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), of the Registrable
Securities, in accordance with the terms of the Registration Rights Schedule (the “Registration Rights Schedule”)
to which this document is annexed. A copy of the Registration Rights Schedule is available from the Company upon request at the
address set forth below. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration
Rights Schedule.

 

Certain legal
consequences arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly,
holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences
of being named or not being named as a selling stockholder in the Registration Statement and the related prospectus.

 

NOTICE

 

The undersigned
beneficial owner (the “Selling Stockholder”) of Registrable Securities hereby elects to include the Registrable
Securities owned by it in the Registration Statement.

 

The undersigned
hereby provides the following information to the Company and represents and warrants that such information is accurate:

 

QUESTIONNAIRE

 

	(a)	 	Full Legal Name of Selling Stockholder:
	 	 
	(b)	 	Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:
	 	 
	(c)	 	Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by this Questionnaire):

1. Name.

 

2. Address
for Notices to Selling Stockholder:

 

    	3

    	 

    

  

	Telephone:	 	 
	 Fax:	 	 
	 	 	 
	Contact Person:	 	 

3. Broker-Dealer
Status:

 

 

 

	 	(a)	Are you a broker-dealer? 

Yes             No
            

 

  

	 	(b)	If “yes” to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to the Company? 

Yes             No
            

   

	 	Note:	If “no” to Section 3(b), the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement. 

  

	 	(c)	Are you an affiliate of a broker-dealer? 

Yes             No
            

   

	 	(d)	If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities? 

Yes             No
            

 

    	4

    	 

    

   

	 	Note:	If “no” to Section 3(d), the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement. 

4. Beneficial
Ownership of Securities of the Company Owned by the Selling Stockholder.

 

Except as
set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company
other than the securities issuable pursuant to the Share Purchase Agreement.

 

	Type and Amount of other securities beneficially owned by the Selling Stockholder: 

  

5. Relationships
with the Company:

 

Except as
set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of
5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship
with the Company (or its predecessors or affiliates) during the past three years.

 

State any
exceptions here:

   

The undersigned
agrees to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur subsequent
to the date hereof at any time while the Registration Statement remains effective.

 

By signing
below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the
inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto.
The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment
of the Registration Statement and the related prospectus and any amendments or supplements thereto.

 

IN WITNESS
WHEREOF the undersigned, by authority duly given, has caused this Selling Stockholder Notice and Questionnaire to be executed and
delivered either in person or by its duly authorized agent.

 

 

 

	Date:	 	 	 	 	 	Beneficial Owner:	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	By:	 	 
	 	 	 	 	 	 	 	Name:	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	Title:	 

  

PLEASE FAX
A COPY (OR EMAIL A .PDF COPY) OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY OVERNIGHT MAIL,
TO:

 

    	5EXECUTION VERSION

 

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

 

This Amended and Restated
Employment Agreement (this “Agreement”), dated as of November 21, 2013 (the “Effective Date”),
by and between Crossroads Systems Inc., a Delaware corporation (the “Company”), and Richard
K. Coleman, Jr., an individual currently residing at 43 Glenmoor Drive, Cherry Hills Village, CO 80113 (“Executive”).

 

WHEREAS, the
Company is currently employing Executive as Interim President and Chief Executive Officer pursuant to the terms of the Employment
Agreement, effective as of May 8, 2013, between the Company and Executive (the “Original Employment Agreement”);

 

WHEREAS, the
Company desires to retain Executive as its President and Chief Executive Officer on a non-interim basis; and

 

WHEREAS, in
connection therewith, the Company and Executive desire to enter into this Agreement.

 

PART ONE - DEFINITIONS

 

Definitions.
For purposes of this Agreement, the following definitions will be in effect:

 

“Affiliates”
means all persons and entities directly or indirectly controlling, controlled by or under common control with the entity specified,
where control may be by management authority, contract or equity interest.

 

“Board”
means the Board of Directors of the Company or the Compensation Committee thereof (or any other committee subsequently granted
authority by the Board), subject to Section 13 below.

 

“Change
of Control” means a change in the ownership or control of the Company effected through any of the following transactions:
(i) a merger, consolidation or reorganization approved by the Company’s stockholders, unless securities representing more
than fifty percent (50%) of the total combined voting power of the voting securities of the successor corporation are immediately
thereafter beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially
owned the Company’s outstanding voting securities immediately prior to such transaction, (ii) any stockholder-approved sale,
transfer or other disposition of all or substantially all of the Company’s assets, (iii) the acquisition, directly or indirectly,
by any person or related group of persons (other than the Company or a person that directly or indirectly controls, is controlled
by or is under common control with, the Company) of beneficial ownership (within the meaning of Rule 13d-3 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”)) of securities possessing more than fifty percent (50%)
of the total combined voting power of the Company’s outstanding securities pursuant to a tender or exchange offer made directly
to the Company’s stockholders; or (iv) a change in the composition of the Board over a period of thirty-six (36) consecutive
months or less such that a majority of the Board members ceases, by reason of one or more contested elections for Board membership,
to be comprised of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have
been elected or nominated for election as Board members during such period by at least a majority of the Board members described
in clause (A) who were still in office at the time the Board approved such election or nomination. Notwithstanding the foregoing,
however, in any circumstance or transaction in which compensation payable pursuant to this Agreement would be subject to the tax
under Section 409A of the Code if the foregoing definition of “Change of Control” were to apply, but would not be so
subject if the term “Change of Control” were defined herein to mean a “change in control event” within
the meaning of Treasury Regulation § 1.409A-3(i)(5), then “Change of Control” means, but only to the extent necessary
to prevent such compensation from becoming subject to the tax under Section 409A of the Code, a transaction or circumstance that
satisfies the requirements of both (1) a Change of Control under the applicable clauses (i) through (iv) above, and (2) a “change
in control event” within the meaning of Treasury Regulation Section § 1.409A-3(i)(5).

 

    	-1-

    	 

    

 

“Code”
means the Internal Revenue Code of 1986, as amended from time to time, and the Treasury regulations and administrative guidance
promulgated thereunder.

 

“Company”
means, unless the context otherwise requires, Crossroads Systems Inc., a Delaware corporation, and all of its subsidiaries.

 

“Compensation
Committee” means the Compensation Committee of the Board.

 

“Employment
Period” means the period beginning on the Effective Date and ending on the last day of the last Term pursuant to
Section 3.

 

“Good Reason”
shall mean the occurrence of any of the following without Executive’s consent: (i) a material reduction of Executive’s
duties or responsibilities, relative to Executive’s duties or responsibilities as in effect immediately prior to such reduction;
(ii) a reduction of more than fifteen percent (15%) in Executive’s Base Salary as in effect immediately prior to such reduction;
(iii) a reduction of more than fifteen percent (15%) by the Company in the kind or level of employee benefits, including bonuses,
for which Executive was eligible (although amounts actually earned will vary) immediately prior to such reduction, with the result
that Executive’s overall benefits package is materially reduced, excluding any equity component thereof; (iv) the relocation
of Executive to a facility or a location more than twenty-five (25) miles from either (1) the Company’s present location
in Austin, Texas or (2) Denver, Colorado; provided, however, than a reduction that is generally applicable to all
executives of the Company shall not constitute “Good Reason” under clauses (ii) and (iii) hereof.

 

“Termination
for Cause” shall mean the Company’s termination of Executive’s employment for any of the following reasons:
(i) Executive’s commission of any act of fraud, embezzlement or dishonesty, (ii) the conviction of Executive, or the entry
of a plea of nolo contendere by Executive, for a felony; (iii) Executive’s unauthorized use or disclosure of any confidential
information or trade secrets of the Company, (iv) any intentional misconduct by Executive, whether by omission or commission, which
has a material adverse effect upon the Company’s business or affairs as determined in the reasonable, good faith discretion
of the Company’s Board of Directors (excluding Executive therefrom), (v) Executive’s breach of Executive’s Confidentiality,
Proprietary Information and Inventions Agreement (the “PIIA”) with the Company, (vi) Executive’s
violation of a published Company policy which stipulates the Executive may be terminated by the Company for cause; or (vii) Executive’s
continued failure, in the reasonable good faith determination of the Board (excluding Executive therefrom), to perform the major
duties, functions and responsibilities of Executive’s position after written notice from the Company identifying the deficiencies
in Executive’s performance and a reasonable cure period of not less than thirty (30) days.

 

    	-2-

    	 

    

 

PART TWO - TERMS AND CONDITIONS OF EMPLOYMENT

 

The following terms
and conditions will govern Executive’s employment with the Company throughout the Employment Period and will also, to the
extent expressly indicated below, remain in effect following Executive’s cessation of employment with the Company.

 

1.Employment
and Duties. During the Employment Period, Executive will serve as the President and Chief Executive Officer of Crossroads Systems,
Inc. and will report to the Board. Executive will have such duties and responsibilities as are commensurate with such position
and such other duties and responsibilities commensurate with such position (including with the Company’s subsidiaries) as
are from time to time assigned to Executive by the Board (or a committee thereof). During the Employment Period, Executive will
devote his full business time, energy and skill to the performance of his duties and responsibilities hereunder, provided the foregoing
will not prevent Executive from (a) serving as a non-executive director on the board of directors of non-profit organizations and
other companies, (b) participating in charitable, civic, educational, professional, community or industry affairs, (c) managing
his and his family’s personal investments, or (d) such other activities approved by the Board from time to time; provided,
that such activities individually or in the aggregate do not interfere or conflict with Executive’s duties and responsibilities
hereunder, violate applicable law, or create a potential business or fiduciary conflict.

 

2.Service as
Director. As of the Effective Date, Executive is serving as a member of the Board. For as long as Executive shall continue
to serve as a member of the Board, he shall stand for re-election to such position at each annual meeting of the Company’s
stockholders. Executive’s failure to be re-elected to the Board, in and of itself, shall not constitute a termination of
this Agreement (and shall not constitute a Termination for Cause or a resignation by Executive for Good Reason, each as defined
in this Agreement), nor shall it entitle Executive to any severance benefits. Pursuant to the Company’s policies,
for the duration of this Agreement, Executive will fulfill his duties as a director without additional compensation. This Agreement
shall not in any way be construed or interpreted so as to affect adversely or otherwise impair the right of the Company or the
stockholders to remove the Executive from the Board at any time in accordance with the provisions of applicable law.

 

3.Term.
The term of this Agreement shall run for a period of from the Effective Date through November 20, 2016 (such period, the “Initial
Term”), and may be terminated earlier as contemplated by Section 8.A. Following the expiration of the Initial
Term, this Agreement shall renew for successive, additional one-year terms (any subsequent extension period being an “Extension
Term”, and the period in which this Agreement is in effect being the “Term”) unless the
Board or Executive provides notice of intent not to renew this Agreement at least thirty days’ prior to the expiration of
the Initial Term or any Extension Term. Termination of this Agreement due to its non-renewal shall not constitute a Termination
for Cause or a resignation by Executive for Good Reason.

 

    	-3-

    	 

    

 

4.Compensation;
Performance Bonus.

 

A.Base Salary.
Executive’s base salary (the “Base Salary”) will be paid at the rate of $22,916.67 monthly
($275,000 annualized) during the Term. Executive’s Base Salary may be increased by the Compensation Committee and/or Board
in their sole discretion, but shall not be decreased without Executive’s consent. Executive’s Base Salary will be paid
at periodic intervals in accordance with the Company’s normal payroll practices for salaried employees.

 

B.Performance
Bonus.

 

a.Executive will
be eligible for (1) a quarterly performance bonus at the end of each fiscal quarter during the Initial Term and each subsequent
Term, under Section 3, with a target value of $50,000.00 per fiscal quarter, and (2) an annual performance bonus at the end
of each fiscal year (commencing with the fiscal year ending October 31, 2014) during the Initial Term and each subsequent Term,
under Section 3, with a target value of $75,000 per fiscal year, which bonuses are to be based upon satisfaction of certain
performance objectives. Notwithstanding the Effective Date of this Agreement, Executive’s target quarterly performance bonus
for the fiscal quarter ending January 31, 2014 shall be $50,000, and Executive’s target annual performance bonus for the
fiscal ending October 31, 2014 shall be $75,000.

 

b.The performance
objectives for these performance bonuses will be developed promptly for the fiscal quarter ending January 31, 2014 and fiscal year
ending October 31, 2014, and periodically by the Compensation Committee for any subsequent fiscal quarters or fiscal years during
the Term; and the Compensation Committee (or its Chairman) will meet and consult with Executive regarding the performance objectives
by which the incentive bonus will be measured (which objectives will be finally determined by the Compensation Committee in its
sole discretion). The performance objectives are expected, but not required, to be based upon objectives such as (i) monetization
of various parts of the Company’s intellectual property portfolio over specified time frames, (ii) cash position and/or cash
flow and/or (iii) net income, profit or other earnings and operating performance measures.

 

c.In the event
that the Compensation Committee, in its sole discretion, determines that the performance bonus criteria have not been satisfied
in full for a fiscal quarter or fiscal year, the performance bonus can be earned on a partial basis as determined by the Compensation
Committee in its sole discretion. Following each fiscal quarter and fiscal year, as applicable, the Compensation Committee will
use good faith efforts to make each quarterly or annual bonus determination promptly after the information relevant to such quarterly
or annual bonus (such as Company financial results, if relevant to the determination of bonus amounts) becomes available to the
Compensation Committee. In all events the relevant performance bonus, except such bonuses payable due to a Change of Control, shall
be paid on the 45th day following (i) the end of such fiscal quarter or (ii) the end of such fiscal year, as applicable.

 

    	-4-

    	 

    

 

d.Except as contemplated
by the following sentence, Executive must be employed by the Company on the last day of a fiscal quarter or fiscal year in order
to be eligible to receive a performance bonus for such quarter or year, as applicable. In the event of a Change of Control, that
occurs during the Employment Period, (i) Executive shall be entitled to receive fiscal quarter and fiscal year performance bonuses
for such periods, (ii) the performance criteria for the performance bonus the fiscal quarter and fiscal year in which such Change
of Control occurs will be deemed to have been achieved at the target value of the performance bonus for that fiscal quarter and
fiscal year, and (iii) the performance bonuses for the fiscal quarter and fiscal year in which such Change of Control occurs will
be paid on the date of the closing of the transaction that gives rise to the Change of Control. For the avoidance of doubt, Executive
shall only be entitled to one performance bonus payment with respect to any fiscal quarter or fiscal year.

 

e.All bonuses pursuant
to this Section 4B are subject to final approval by the Compensation Committee.

 

C.The Company may
deduct and withhold, from the compensation payable and benefits provided to Executive hereunder, any and all applicable federal,
state, local and other taxes and any other amounts required to be deducted or withheld by the Company under applicable statute
or regulation.

 

D.To the extent that
any compensation paid or payable pursuant to this Agreement is considered “incentive-based compensation” within the
meaning and subject to the requirements of Section 10D of the Exchange Act, such compensation shall be subject to potential
forfeiture or recovery by the Company in accordance with any compensation recovery policy adopted by the Board or any committee
thereof in response to the requirements of Section 10D of the Exchange Act and any implementing rules and regulations thereunder
adopted by the Securities and Exchange Commission or any national securities exchange on which the Company’s common stock
is then listed. This Agreement may be unilaterally amended by the Company to comply with any such compensation recovery policy.

 

5.Equity Compensation.

 

A.The Company will
grant Executive stock options under the Crossroads Systems, Inc. 2010 Stock Incentive Plan (the “2010 Stock Plan”)
to purchase a total of 450,000 shares of the Company’s common stock at an exercise price equal to the fair market value of
the Company’s common stock on such date as determined in accordance with the 2010 Stock Plan (the “Options”).
Subject to Executive’s continuous employment with the Company, one-eighth (1/8th) of the Options shall vest at the end of
each of the Company’s fiscal quarters, with the first 1/8th vesting on January 31, 2014; provided, however,
that all of the unvested Options shall vest (i) in full upon the consummation of a Change of Control and (ii) pursuant to the terms
of Section 8. The Options shall expire on, and shall not be exercisable after, a date that is not later than the tenth anniversary
of the date of grant (the “Final Exercise Date”).

 

B.Executive will
be eligible for additional option grants as determined by the Board or the Compensation Committee in their sole discretion.

 

    	-5-

    	 

    

 

C.Notwithstanding
anything in this Agreement to the contrary, the Options and the grants and terms thereof shall be subject in all respects to the
terms of the 2010 Stock Plan, as it may be amended from time to time, and this Agreement shall not amend or be deemed to amend
the 2010 Stock Plan.

 

6.Expense Reimbursement;
Fringe Benefits; Paid Time Off (PTO).

 

A.Executive will
be entitled to reimbursement from the Company for the following expenses incurred by Executive during the Initial Term or the Term:
(i) all reasonable temporary living expenses associated with his residence in or around Austin, TX, (ii) Executive’s regular
travel between Austin, TX and his place of residence in the USA, (iii) car rental and associated expenses, including fuel, or mileage
while in Austin, TX, (iv) the cost to Executive of health care premiums under an insurance policy other than that provided by the
Company’s group health plan, but only up to the value of the Company’s portion of group health premiums under the Company’s
group health plan coverage for individuals only, and (v) customary, ordinary and necessary business expenses incurred by Executive
in the performance of Executive’s duties hereunder, provided that Executive’s entitlement to such reimbursements shall
be conditioned upon Executive’s provision to the Company of vouchers, receipts and other substantiation of such expenses
in accordance with Company policies.

 

B.During the Employment
Period, Executive will be eligible to participate in any group life insurance plan, group medical and/or dental insurance plan,
accidental death and dismemberment plan, short-term disability program and other employee benefit plans, including profit sharing
plans, cafeteria benefit programs and stock purchase and option plans, which are made available to executives of the Company and
for which Executive qualifies under the terms of such plan or plans.

 

C.Executive shall
be eligible for vacation and paid time off (PTO) in accordance with the Company’s policies as in effect from time to time.
Currently, the Company does not accrue for any vacation or paid time off and, accordingly, Executive would not be eligible to be
paid any amounts with respect thereto upon termination of his employment.

 

7.Executive
Covenants.

 

A.Moonlighting.
During the Employment Period, except as permitted by Section 1, Executive will not directly or indirectly, whether for Executive’s
own account or as an employee, director, consultant or advisor, provide services to any business enterprise other than the Company,
unless otherwise authorized by the Board in writing.

 

    	-6-

    	 

    

 

B.Transition and
Other Assistance. During the 30 days following the termination of the Employment Period, Executive will take all actions the
Company may reasonably request to maintain the Company’s business, goodwill and business relationships and to assist with
transition matters, all at Company expense. In addition, upon the receipt of notice from the Company (including outside counsel),
during the Employment Period and thereafter, Executive will respond and provide information with regard to matters in which he
has knowledge as a result of his employment with the Company, and will provide assistance to the Company and its representatives
in the defense or prosecution of any claims that may be made by or against the Company, to the extent that such claims may relate
to the period of Executive’s employment with the Company, all at Company expense. During the Employment Period and thereafter,
Executive shall promptly inform the Company if he becomes aware of any lawsuits involving such claims that may be filed or threatened
against the Company. During the Employment Period and thereafter, Executive shall also promptly inform the Company (to the extent
he is legally permitted to do so) if he is asked to assist in any investigation of the Company (or its actions), regardless of
whether a lawsuit or other proceeding has then been filed against the Company with respect to such investigation, and will not
do so unless legally required. The Company will pay Executive at a rate of $350 per hour, plus reasonable expenses, in connection
with any actions requested by the Company under this paragraph following any termination of Executive’s employment, with
such amounts being paid to Executive at periodic intervals in accordance with the Company’s normal payroll practices for
salaried employees. Executive’s obligations under this paragraph shall be subject to the Company’s reasonable cooperation
in scheduling in light of Executive’s other obligations.

 

C.Other Agreements
Between Executive and Company. Nothing herein shall be deemed to modify or waive the Company’s and Executive’s
rights and obligations under Executive’s PIIA or Executive’s Indemnity Agreement, each signed by Executive and each
incorporated herein by this reference.

 

D.Survival of
Provisions. The obligations contained in this Section 7 will survive the termination of Executive’s employment with
the Company and will be fully enforceable thereafter.

 

8.Termination
of Employment.

 

A.General.
Subject to Section 8.D, Executive’s employment with the Company is “at-will” and may be terminated at any
time by either Executive or the Company for any reason (or no reason) in accordance with this Agreement, which will also result
in the Term ending, by the party seeking to terminate Executive’s employment providing written notice of such termination
to the other party; provided, however, that in the event that Executive gives notice of termination to the Company, the
Company may, in its sole discretion, make such termination effective earlier than any notice date.

 

B.Death and Permanent
Disability. Upon termination of Executive’s employment for the Company due to death or permanent disability during the
Term, the employment relationship created pursuant to this Agreement will immediately terminate, the Term will end and amounts
will only be payable under this Agreement as specified in this Section 8.B. Should Executive’s employment with the Company
terminate by reason of Executive’s death or permanent disability during the Employment Period, Executive shall be entitled
to receive:

 

a.the unpaid Base
Salary earned by Executive pursuant to Section 4.A for services rendered through the date of Executive’s death or permanent
disability, as applicable, payable in accordance with the Company’s normal payroll practices for terminated salaried employees;

 

    	-7-

    	 

    

 

b.reimbursement
of all expenses for which Executive is entitled to be reimbursed pursuant to Section 6.A, payable in accordance with the Company’s
normal reimbursement practices;

 

c.the right to
continue health care benefits under the Consolidated Omnibus Budget Reconciliation Act of 1986, as amended, at Executive’s
cost, to the extent required and available by law and subject to the Company continuing to maintain a group health plan;

 

d.any accrued but
unpaid quarterly performance bonus or annual performance bonus pursuant to Section 4.B; provided that Executive was employed
by the Company on the last day of the fiscal quarter or fiscal year to which such bonus relates as specified in Section 4.B, payable
at such time as provided in Section 4.B; and

 

e.the limited death,
disability, and/or income continuation benefits provided under Section 6.B, if any, will be payable in accordance with the
terms of the plans pursuant to which such limited death or disability benefits are provided.

 

Compensation and benefits
provided pursuant to Section 8.B.a. through e. are collectively referred to as the “Accrued Obligations.”

 

If Executive’s
death occurs after the end of a fiscal quarter or fiscal year, but before payment of the applicable bonus has been made, payment
of the applicable bonus will be made to the Executive’s estate. For purposes of this Agreement, Executive will be deemed
“permanently disabled” if Executive is so characterized pursuant to the terms of the Company’s disability policies
or programs applicable to Executive from time to time, or if no such policy is applicable, if the Compensation Committee determines,
in its sole discretion, that Executive is unable to perform the essential functions of Executive’s duties for physical or
mental reasons for ninety (90) days in any twelve-month period.

 

C.Termination
for Cause; Resignation without Good Reason. The Company may at any time during the Employment Period, upon written notice summarizing
with reasonable specificity the basis for the Termination for Cause, terminate Executive’s employment hereunder for any act
qualifying as a Termination for Cause. Such termination will be effective immediately upon such notice. Upon any Termination for
Cause (or employee’s resignation other than for Good Reason), Executive shall be solely entitled to receive:

 

a.the unpaid Base
Salary earned by Executive pursuant to Section 4.A for services rendered through the date of Executive’s death or permanent
disability, as applicable, payable in accordance with the Company’s normal payroll practices for terminated salaried employees;

 

b.reimbursement
of all expenses for which Executive is entitled to be reimbursed pursuant to Section 6.A, payable in accordance with the Company’s
normal reimbursement practices; and

 

c.the right to
continue health care benefits under the Consolidated Omnibus Budget Reconciliation Act of 1986, as amended, at Executive’s
cost, to the extent required and available by law and subject to the Company continuing to maintain a group health plan.

 

    	-8-

    	 

    

 

Except as otherwise
provided in in this Agreement, no portion of the performance bonus for the fiscal quarter or fiscal year shall be paid with respect
to the fiscal quarter or fiscal year in which Executive’s employment is terminated during the Employment Period.

 

D.Involuntary
Termination Without Cause by the Company; Resignation by Executive for Good Reason. The Company shall be entitled to terminate
Executive with or without notice, other than a Termination for Cause, and Executive shall be entitled to resign with or without
Good Reason, in each case at any time; provided, however, that if Executive (1) is terminated by the Company other than in circumstances
constituting a Termination for Cause, or (2) resigns for Good Reason, then Executive shall be solely entitled to receive:

 

a.The Accrued Obligations
through the date of termination;

 

b.The immediate
vesting of all Options and all other awards held by Executive under any equity incentive plan that may be adopted by the Board,
except and only to the extent that (i) any agreement with respect to an award specifically provides otherwise and (ii) such vesting
would not result in the imposition of the additional tax under Section 409A of the Code; and

 

c.Subject to Sections
8.E, 8.F, 8.G and 9:

 

(i)An amount equal to the full payout
of 100% of the target of Executive’s (i) quarterly performance bonus for the current fiscal quarter, (ii) quarterly performance
bonus for the next three fiscal quarters, and (iii) and annual performance bonus for the current fiscal year, had Executive remained
employed by the Company through the relevant dates to be eligible for such amounts, payable in a single lump sum on the 60th day
following the date of termination; provided, however, that if Executive’s performance bonus targets for any
future fiscal quarter or fiscal year have not been established at the time of termination, such payment targets shall be deemed
to be equal to the last-established payment targets for a fiscal quarter or fiscal year, as applicable; and

 

(ii)Severance pay at a rate equal
to 100% of Executive’s monthly Base Salary, as then in effect (less applicable withholding taxes), payable for twelve (12)
months beginning on the 60th day after the date of such termination, to be paid in substantially equivalent installments in accordance
with the Company’s normal payroll practices.

 

The compensation and benefits provided pursuant to Section 8.D.c
are collectively referred to as the “Severance Benefits.”

 

d.For purposes
of clarity, a termination of Executive’s employment due to Executive’s death or to Executive’s permanent disability
shall not be considered either a termination by the Company without cause or a resignation by Executive for Good Reason, and such
termination shall not entitle Executive (or his heirs or representatives) to any compensation or benefits pursuant to this Section
8.D.

 

    	-9-

    	 

    

 

E.Certain Conditions
Regarding Severance Benefits. All Severance Benefits contemplated by Section 8.D.c above are conditional on Executive: (a)
signing a release substantially in the form attached hereto as Exhibit A (the “Release”),
and (b) the non-revocation of the ADEA Release (as defined in the Release); provided that such Release (including the ADEA
Release) becomes effective and irrevocable no later than sixty (60) days following the termination date or such earlier date required
by the Release (such deadline, the “Release Deadline”). If the Release (including the ADEA Release) does
not become effective by the Release Deadline, Executive will forfeit any rights to all Severance Benefits. In addition, if Executive
violates the terms of the PIIA: (i) prior to the date that the Release becomes effective and irrevocable, then Executive will forfeit
any rights to all Severance Benefits, or (ii) following the date the Release becomes effective and irrevocable, then Executive
(x) must immediately repay all Severance Benefits previously paid to Executive by the Company and (y) will forfeit any rights to
all future Severance Benefits.

 

F.Resignations
from Other Positions. Upon any termination of Executive’s employment, and as a condition to Executive receiving any Severance
Benefits under this Agreement, if so requested by a majority of the Board, Executive will immediately resign (1) as a director
of the Company and any of its subsidiaries, (2) from all officer or other positions of the Company and (3) from all fiduciary positions
(including as trustee) Executive then holds with respect to any employee benefit plans or trusts established, maintained or sponsored
by the Company or by any of its Affiliates. Failure by Executive to resign immediately from all positions described in the immediately
preceding sentence shall result in automatic forfeiture of any and all rights to the Severance Benefits.

 

G.Options Upon
Termination. Except as otherwise provided in Section 8, upon termination of Executive’s employment for any reason and
subject to the terms of the 2010 Stock Plan, as it may be amended from time to time, including by reason of Executive’s death
or permanent disability, any portion of any options held by the Executive that are not then vested will immediately be forfeited
and expire for no consideration and the remainder of such options will remain exercisable for twelve months thereafter (with the
understanding that any options that are intended to be “incentive stock options” under the Code shall thereupon be
disqualified from such treatment); provided, that any portion of the options held by Executive immediately
prior to Executive’s death, to the extent then exercisable, will remain exercisable for one year following Executive’s
death; and provided, further, that in no event shall any portion of the options be exercisable after the Final Exercise
Date.

 

9.Section 409A
of the Code.

 

A.General.
This Agreement shall be interpreted and applied in all circumstances in a manner that is consistent with the intent of the parties
that, to the extent applicable, amounts earned and payable pursuant to this Agreement shall constitute short-term deferrals exempt
from the application of Section 409A of the Code and, if not exempt, that amounts earned and payable pursuant to this Agreement
shall not be subject to the premature income recognition or adverse tax provisions of Section 409A of the Code.

 

B.Separation
from Service. References in this Agreement to “termination” of Executive’s employment, “resignation”
by Executive from employment and similar terms shall, with respect to such events that will result in payments of compensation
or benefits, mean for such purposes a “separation from service” as defined under Section 409A of the Code.

 

    	-10-

    	 

    

 

C.Specified Executive.
In the event any one or more amounts payable under this Agreement constitute a “deferral of compensation” and become
payable on account of the “separation from service” (as determined pursuant to Section 409A of the Code) of Executive
and if as such date Executive is a “specified employee” (as determined pursuant to Section 409A of the Code), such
amounts shall not be paid to Executive before the earlier of (i) the first day of the seventh calendar month beginning after the
date of Executive’s “separation from service” or (ii) the date of Executive’s death following such
“separation from service.” Where there is more than one such amount, each shall be considered a separate payment and
all such amounts that would otherwise be payable prior to the date specified in the preceding sentence shall be accumulated (without
interest) and paid together on the date specified in the preceding sentence.

 

D.Separate Payments.
For purposes of Section 409A of the Code, each payment or amount due under this Agreement shall be considered a separate payment,
and Executive’s entitlement to a series of payments under this Agreement is to be treated as an entitlement to a series of
separate payments.

 

E.Reimbursements.
Any reimbursement to which Executive is entitled pursuant to this Agreement that would constitute nonqualified deferred compensation
subject to Section 409A of the Code shall be subject to the following additional rules: (i) no reimbursement of any such expense
shall affect Executive’s right to reimbursement of any other such expense in any other taxable year; (ii) reimbursement of
the expense shall be made, if at all, not later than the end of the calendar year following the calendar year in which the expense
was incurred; (iii) the right to reimbursement shall not be subject to liquidation or exchange for any other benefit; and
(iv) the right to reimbursement of expenses incurred kind shall terminate one year after the end of the Employment Period.

 

10.No Guarantee
of Tax Consequences. The Board, the Compensation Committee, the Company and its Affiliates, officers and employees make no
commitment or guarantee to Executive that any federal, state, local or other tax treatment will apply or be available to Executive
or any other person eligible for compensation or benefits under this Agreement and assume no liability whatsoever for the tax consequences
to Executive or to any other person eligible for compensation or benefits under this Agreement.

 

11.Choice of
Law; Jurisdiction. The provisions of this Agreement will be construed and interpreted under the laws of the State of Delaware,
excluding such jurisdiction’s conflict of laws principles. Each of the parties irrevocably consents to the exclusive personal
jurisdiction of the federal and state courts located in Travis County, Texas, as applicable, for any matter arising out of or relating
to this Agreement.

 

12.Entire Agreement;
Severability. This Agreement and the agreements referenced herein contain the entire agreement of the parties relating to the
subject matter hereof, and supersede in their entirety any and all prior agreements, understandings or representations relating
to the subject matter hereof, including the terms of the Original Employment Agreement. For the avoidance of doubt, except to the
extent specified herein, Executive shall have no rights under the Original Employment Agreement. No agreements or representations,
oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly
set forth in this Agreement. The provisions of this Agreement shall be deemed severable and, if any provision is found to be illegal,
invalid or unenforceable for any reason, (a) the provision will be amended automatically to the minimum extent necessary to cure
the illegality or invalidity and permit enforcement and (b) the illegality, invalidity or unenforceability will not affect the
legality, validity or enforceability of the other provisions hereof.

 

    	-11-

    	 

    

 

13.Amendment;
Committee Authority. This Agreement may be amended, supplemented, or modified only by a written instrument duly executed by
or on behalf of each party hereto. All determinations and other actions required or permitted hereunder to be made by or on behalf
of the Company or the Board may be made by either the Board (excluding Executive therefrom) or the Compensation Committee (or any
other committee subsequently granted authority by the Board); provided that the actions of the Compensation Committee (or
any other committee subsequently granted authority by the Board) shall be subject to the authority then vested in such committee
by the Board, it being understood and agreed that as of the date of this Agreement the Compensation Committee has full authority,
concurrent with the Board, to administer this Agreement; and provided, further, that a decision or action by the
Compensation Committee (or any other committee subsequently granted authority by the Board) hereunder shall be subject to review
or modification by the Board if the Board so chooses.

 

14.Waiver. 
The rights and remedies of the parties to this Agreement are cumulative and not alternative. Neither the failure nor any delay
by either party in exercising any right, power, or privilege under this Agreement will operate as a waiver of such right, power,
or privilege, and no single or partial exercise of any such right, power, or privilege will preclude any other or further exercise
of such right, power, or privilege or the exercise of any other right, power, or privilege. To the maximum extent permitted by
applicable law, (a) no claim or right arising out of this Agreement can be discharged by one party, in whole or in part, by a waiver
or renunciation of the claim or right unless in writing signed by the other party; (b) no waiver that may be given by a party will
be applicable except in the specific instance for which it is given; and (c) no notice to or demand on one party will be deemed
to be a waiver of any obligation of such party or of the right of the party giving such notice or demand to take further action
without notice or demand as provided in this Agreement.

 

15.Representations
and Warranties by Executive. Executive represents and warrants to the Company that: (a) Executive has the legal right
to enter into this Agreement and to perform all of the obligations on Executive’s part to be performed hereunder in accordance
with its terms; (b) Executive is not a party to any contract, agreement or understanding, written or oral, which could prevent
Executive from entering into this Agreement or performing all of his duties and responsibilities hereunder; and (c) Executive
is not a party to any agreement containing any non-competition, non-solicitation, confidentiality or other restrictions on Executive’s
activities. Executive further represents and warrants to the Company that, to the best of his knowledge, information and belief,
Executive is not aware of any action taken by Executive (or any failure to act) that could form the basis for a breach of fiduciary
duty or related claim against Executive by any current or former employer.

 

    	-12-

    	 

    

 

16.Assignment.
Notwithstanding anything else herein, this Agreement is personal to Executive and neither this Agreement nor any rights hereunder
may be assigned by Executive. The Company may assign this Agreement to an affiliate or to any acquiror of all or substantially
all of the business and/or assets of the Company, in which case the term “Company” will mean such affiliate or acquiror.
This Agreement will inure to the benefit of and be binding upon the personal or legal representatives, executors, administrators,
successors, heirs, distributees, devisees, legatees and permitted assignees of the parties.

 

17.Arbitration.
Executive agrees that all disagreements, disputes and controversies between Executive and the Company arising under or in connection
with this Agreement will be settled by arbitration conducted before a single arbitrator mutually agreed to by the Company and Executive,
sitting in Austin, Texas or such other location agreed to by Executive and the Company, in accordance with the Commercial Arbitration
Rules of the American Arbitration Association then in effect; provided, however, that if the Company and Executive are unable
to agree on a single arbitrator within 30 days of the demand by another party for arbitration, an arbitrator will be designated
by the Texas Office of the American Arbitration Association. The determination of the arbitrator will set forth in writing findings
of fact and conclusions of law upon which the determination was based, and will be final and binding on Executive and the Company.
Each party waives right to trial by jury and further review or appeal of the arbitrator’s ruling. Judgment may be entered
on the award of the arbitrator in any court having proper jurisdiction. The arbitrator will, in its award, allocate between the
parties the costs of arbitration, including the arbitrator’s fees and expenses, in such proportions as the arbitrator deems
just. Each party shall pay its own attorneys’ fees and expenses in connection with any such arbitration.

 

18.Counterparts,
Facsimile. This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy
of this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement. To the maximum
extent permitted by applicable law, this Agreement may be executed via facsimile.

 

19.Notices.
Any notice required to be given under this Agreement shall be deemed sufficient, if in writing, and sent by certified mail,
return receipt requested, via overnight courier, or hand delivered to the Company at 11000 North MoPac Expressway, Austin, Texas
78759, Attn: Chairman of the Compensation Committee and Chief Financial Officer, and to Executive at the most recent address reflected
in the Company’s employment records.

 

Signature page follows.

 

    	-13-

    	 

    

 

IN WITNESS WHEREOF,
the Company and Executive have executed this Amended and Restated Employment Agreement to be effective as of the Effective Date.

 

	CROSSROADS SYSTEMS, INC.	 	Richard K. Coleman, Jr.	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	By:  	/s/ Jeffrey E. Eberwein	 	/s/ Richard K. Coleman, Jr.	 
	Name:  	Jeffrey E. Eberwein	 	 	 
	Title:	Chairman of the Board of Directors	 	 	 

 

    	-14-

    	 

    

 

EXHIBIT A

 

FORM OF RELEASE AGREEMENT

 

Crossroads Systems, Inc.

 

Employment Termination Date: _______________________

 

1.Introduction
and General Information. Signing this release (this “Release”) is one condition to receiving
certain benefits offered by Crossroads Systems, Inc. (the “Company”) that are in addition to anything
of value to which you already are entitled. Reference is made to that certain Amended and Restated Agreement dated November 21,
2013 (the “Agreement”) between you and the Company. Capitalized terms used but not defined herein shall
have the meanings ascribed to such terms in the Agreement.

 

The Agreement provides that the Company
will provide certain consideration, if among other requirements, you execute and deliver this Release and do not revoke the ADEA
Release (as defined below) following your termination date and within the periods specified in Section 2(b), as set forth
below. You should thoroughly review and understand the effect of this Release before signing it. To the extent you have any claims
covered by this Release, you will be waiving potentially valuable rights by signing this Release. You also are advised to discuss
this Release with your attorney.

 

2.Releases.

  

(a)General Release.
You agree that the foregoing consideration (including the consideration to be provided pursuant to the Agreement) represents settlement
in full of all outstanding obligations owed to you by the Company and its current and former officers, directors, employees, agents,
investors, attorneys, shareholders, administrators, affiliates, divisions, subsidiaries, predecessor and successor corporations,
and assigns (collectively, the “Releasees”). You (for yourself, your spouse, executors, heirs, beneficiaries,
representatives, agents, attorneys, assigns, insurers and assurers, and anyone claiming by or through him) hereby and forever release
the Releasees from any and all manner of actions, causes of action, suits, charges, claims, complaints, counterclaims, defenses,
demands, damages or liabilities whatsoever, including, without limitation, attorneys’ fees, known or unknown, accrued or
which may ever accrue, whether based in contract or tort, statutory or common law, of every kind and nature whatsoever, arising
from the beginning of time to the execution date of this Release, and hereafter, whether or not relating to or arising from your
employment and termination of employment with the Company and any act that has occurred as of the date of the execution of this
Release in connection with any service that you may have rendered or may have been requested to render to or on behalf of the Company
at any time, other than the rights and obligations under this Release, and except as to claims arising under the Age Discrimination
in Employment Act (“ADEA”), which are addressed in subsection (b) below. Except as to claims arising
under the ADEA, which are covered in subsection (b) below, and as provided for in subsection (c) below, this Release shall be construed
as broadly as possible and shall include without limitation: (i) any contractual or other claims of employment, benefits, or payment
you may have; (ii) any claims arising out of or in connection with the initiation, termination or existence of your employment
relationship with the Company or any service performed on behalf of the Company; (iii) any claims regarding wages and/or compensation
in any form whatsoever, vacation, leaves, bonuses, commissions, monies, perquisites, benefits, severance, or any other item attributable
to or arising in connection with your employment with the Company; (iv) any and all claims relating to the issuance of all outstanding
shares of capital stock of the Company; and (v) without limitation, claims, if any, arising under the following:

 

    	A-1

    	 

    

 

		·	Title VII of the Civil Rights Act of 1964, as amended;

		·	The Americans with Disabilities Act of 1990, as amended;

		·	The Fair Labor Standards Act of 1938, as amended;

		·	The Family and Medical Leave Act of 1993;

		·	The Employee Retirement Income Security Act of 1974 (ERISA), as amended (non-vested rights);

		·	The Occupational Safety and Health Act of 1970 (OSHA), as amended;

		·	Texas Labor Code § 21.001, et seq. (Texas Employment Discrimination);

		·	Texas Labor Code § 61.001, et seq. (Texas Pay Day Act);

		·	Austin, Texas Code of Ordinance, Title V, Chapters 5-3, 5-5 and 5-6;

		·	any other federal, state or local civil or human rights law or other local, state or federal law, regulation or ordinance;

		·	any public policy, contract, tort, or common law (including, without limitation, those relating to fraud, whistleblower, retaliation,
negligent or intentional conduct of any nature, constructive discharge, emotional distress, personal injury); or

		·	intentional conduct of any nature, constructive discharge, emotional distress, personal injury.

 

(b)ADEA Release.
For the good and valuable consideration provided for under the Agreement, the sufficiency of which is hereby acknowledged, and
to which you acknowledge you are not otherwise entitled, and other valuable consideration, the sufficiency of which is hereby acknowledged,
you hereby completely and forever release and irrevocably discharge each of the Releasees, of and from any and all liabilities,
claims, actions, demands, and/or causes of action, arising under the ADEA on or before the date of this Release (the “ADEA
Release”), and hereby acknowledge and agree that: the Agreement and this Release, including this ADEA Release, was
negotiated at arms’ length; the Agreement and this Release, including the ADEA Release, is worded in a manner that you fully
understand; you specifically waive any rights or claims under the ADEA; you knowingly and voluntarily agree to all of the terms
set forth in the Agreement and this Release, including this ADEA Release; you acknowledge and understand that any claims under
the ADEA that may arise after the date of this Release are not waived; the rights and claims waived in this Release and this ADEA
Release are in exchange for consideration over and above anything to which you were already undisputedly entitled; you have been
and hereby are advised in writing to consult with an attorney prior to executing the Agreement, this Release and the ADEA Release;
you understand that you have been given a period of up to twenty-one (21) days to consider the ADEA Release prior to executing
it; and you understand that you have been given a period of seven (7) days from the date of the execution of the ADEA Release to
revoke the ADEA Release, and understand and acknowledge that the ADEA Release will not become effective or enforceable until the
revocation period has expired. If you elect to revoke this ADEA Release, revocation must be in writing and presented to the Board
of Directors or their designee within seven (7) days from the date of the execution of the Release.

 

    	A-2

    	 

    

 

(c)Notwithstanding
the foregoing, by executing this Release, you shall not be deemed to have waived any rights with respect to your right to exercise
vested stock options or your ownership of vested capital stock of the Company (although pursuant to this subsection (c), you are
expressly waiving and releasing any and all claims, including any shareholder derivative claims, that you may have had from the
beginning of time through the date of this Release as a stockholder of the Company). Furthermore, nothing in this Release is intended
to be construed as a release of your rights of indemnification and exculpation for actions as a director, employee or officer of
the Company you have at law or under the governing documents (charter and bylaws) of the Company or any of its Affiliates (as defined
below), any written indemnity agreement with regard to the foregoing, or any D&O insurance coverage under which you may be
covered by in connection with the foregoing; provided that in no event shall you be entitled to make any claim thereunder,
under the Company’s or the Affiliates’ governing documents or insurance policies, or otherwise in defense of, or for
exculpation, indemnification or advancement with respect to your compliance with this Release or your breach or alleged breach
of this Release.

 

(d)Release of
Unknown Claims. You understand and agree, in compliance with any statute or ordinance which requires a specific release of
unknown claims or benefits, that, except where expressly prohibited by law, this Release includes a release of unknown claims,
and you hereby expressly waive and relinquish any and all claims, rights or benefits that you may have which are unknown to you
at the time of the execution of this Release. You understand and agree that if, hereafter, you discover facts different from or
in addition to those that you now know or believe to be true, that the waivers and releases of this Release shall be and remain
effective in all respects notwithstanding such different or additional facts or the discovery of such facts.

 

(e)No Other
Claims; Ownership of Claims. You represent and warrant that you do not presently have on file, and further represent and warrant
to the maximum extent allowed by law that you will not hereafter file, any lawsuits, claims, charges, grievances or complaints
against the Company and/or any of the Releasees in or with any administrative, state, federal or governmental entity, agency, board
or court, or before any other tribunal or panel of arbitrators, public or private, based upon any actions or omissions by the Company
and/or any of the Releasees occurring prior to the date of this Release. To the extent that you are still entitled to file any
administrative charge with any governmental agency, you hereby release any personal entitlement to reinstatement, back pay, or
any other types of damages or injunctive relief in connection with any civil action brought on his behalf after your filing of
any administrative charge. Finally, you represent and agree that you are the sole and lawful owner of all rights, title and interest
in and to all released matters, claims and demands arising out of or in any way related to your employment with the Company and/or
the termination thereof.

 

(f)Company’s
Remedies for Breach. You acknowledge and agree that any breach by you of this Release or of your obligations under the Agreement,
shall constitute a material breach of the Agreement, and shall entitle the Company immediately to recover the consideration provided
to you in connection with the Agreement, except as provided by law. Except as provided by law, you shall also be responsible to
the Company for all costs, attorneys’ fees and any and all damages incurred by the Company in: (a) enforcing your obligations
under this Release and the Agreement, including the bringing of any action to recover the consideration, and (b) defending against
a claim brought or pursued by you in violation of the terms of this Release.

 

    	A-3

    	 

    

 

3.Non-Disparagement.
(a) You agree that you will not, directly or indirectly, disclose, communicate or publish any disparaging or critical information
concerning the Company or any parent or subsidiary of the Company, or any company controlled by the Company, or any other entity
or organization wholly or partially, directly or indirectly, owned or controlled by the Company (each, an “Affiliate”),
their business, financial condition, professional skills or expertise, suppliers, customers or clients, products or services, operations,
market position, performance, technology, employees, officers, directors, consultants, representatives, agents or investors, or
proprietary or technical information whatsoever, or directly or indirectly cause or encourage others to disclose, communicate,
or publish any disparaging or critical information concerning the same and (b) nothing contained in this paragraph is intended
to prevent any person from testifying truthfully in any legal proceeding in which such person is under a subpoena or other court
order to do so.

 

4.No Interference.
You agree that you will not act in any manner that might damage the business of the Company or its Affiliates or the Company’s
investors or their respective affiliates. You agree that you will not, directly or indirectly, counsel or assist any attorneys
or their clients in the presentation or prosecution of any disputes, differences, grievances, claims, charges or complaints by
any third party against the Company or its Affiliates or the Company’s investors or their respective affiliates and/or any
officer, director, employee, agent, representative, shareholder or attorney of any of the foregoing, provided that nothing herein
shall prohibit you from testifying truthfully in any legal proceeding in which you are under a subpoena or other court order to
do so.

 

5.Cooperation.
You agree to cooperate with the Company and its Affiliates, at the Company’s reasonable request and without further consideration,
in all respects concerning any matters which require your assistance, cooperation or knowledge, including communicating with persons
inside or outside the Company and any Affiliate and assistance/availability for any agency, board and legal investigations and
proceedings.

 

6.Confidentiality.
You agrees to keep the terms and conditions of this Release confidential, except for any discussion with family members, accountants,
or legal counsel, or as required by law.

 

7.Severability.
If any provision contained in this Release is determined to be void, illegal or unenforceable, in whole or in part, then the other
provisions contained herein shall remain in full force and effect as if the provision which was determined to be void, illegal
or unenforceable had not been contained herein.

 

8.No Re-Employment.
You acknowledge and agree that by executing this Release, you waive all rights or claims for reinstatement of employment with the
Company. You further agree not to inquire as to, seek or apply for, in any manner whatsoever, any contract or appointment, employment,
commission, job, work, position, duty, station, task, trade, consignment, or any other relationship with the Company, and that
any application for employment to the Company by you will be considered void.

 

    	A-4

    	 

    

 

9.Re-Affirmation.
You agree and acknowledge that your fulfillment of the obligations contained in your Proprietary Information and Inventions Agreement
(your “PIIA”) are necessary to protect the Company’s Intellectual Property Rights (as defined in
your PIIA) and to preserve the Company’s value and goodwill. You further acknowledge the time, geographic and scope limitations
of your obligations not to compete and not to interfere under your PIIA are reasonable, especially in light of the Company’s
desire to protect its Proprietary Information, and that you will not be precluded from gainful employment if you are obligated
not to compete or interfere with the Company pursuant to the terms of your PIIA. Notwithstanding the foregoing, even if you fail
to deliver or if you validly revoke this Release, nothing shall be deemed to affect the validity of your PIIA or the obligations
contained therein.

 

10.Choice
of Law. This Release shall be interpreted under and governed by, construed and enforced in accordance with, and subject
to, the laws of the State of Texas, without giving effect to any principles of conflicts of law.

 

11.Voluntary
Agreement. YOU UNDERSTAND AND AGREE THAT YOU MAY BE WAIVING SIGNIFICANT LEGAL RIGHTS BY SIGNING THIS RELEASE, AND REPRESENT
THAT YOU HAVE ENTERED INTO THIS RELEASE VOLUNTARILY, AFTER HAVING THE OPPORTUNITY TO CONSULT WITH AN ATTORNEY OF YOUR OWN CHOOSING,
WITH A FULL UNDERSTANDING OF THE RELEASE AND ALL OF ITS TERMS.

 

[Signature page follows]

 

    	A-5

    	 

    

 

THE UNDERSIGNED HAS READ AND FULLY CONSIDERED THE RELEASE LANGUAGE
HEREIN AND DESIRES TO ENTER INTO THIS RELEASE. I ALSO HAVE BEEN ADVISED HEREIN IN WRITING TO CONSULT WITH AN ATTORNEY PRIOR TO
SIGNING THIS RELEASE. HAVING ELECTED TO SIGN THIS RELEASE AND RECEIVE THE CONSIDERATION IN THE AGREEMENT, I FREELY AND KNOWINGLY,
AND AFTER DUE CONSIDERATION, ENTER INTO THIS RELEASE INTENDING TO WAIVE, SETTLE AND RELEASE ALL CLAIMS I HAVE OR MIGHT HAVE AGAINST
THE COMPANY AND THE OTHER RELEASED PARTIES AS OF THE DATE I SIGN THIS RELEASE.

 

	 	 	 
	 	Richard K. Coleman, Jr.
	 	 	 
	 	Date:	 

 

 

ACKNOWLEDGED AND ACCEPTED:

CROSSROADS SYSTEMS, INC.

 

	By: 	 	 
	Name: 	 	 
	Title: 	 	 
	Date: 	 	 

 

    	A-6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}]]